☆ 4.6 Article

Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol

REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Obstetrics & Gynecology

A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol

Manuel Fernandez Sanchez et al.

Summary: This study aimed to investigate whether the addition of CG beta to the long GnRH agonist protocol for ovarian stimulation increased the number of good-quality blastocysts. The results showed that the addition of CG beta reduced the number of intermediate follicles and related downstream parameters, including the number of oocytes and blastocysts.

HUMAN REPRODUCTION (2022)

Add to Collection

Letter Obstetrics & Gynecology

Response to: Comparison between follitropin delta and follitropin alfa for ovarian stimulation in context of ART is only scientifically sound and clinically relevant if individualization of starting dose is allowed in both arms!

Bernadette Mannaerts

REPRODUCTIVE BIOMEDICINE ONLINE (2022)

Add to Collection

Article Obstetrics & Gynecology

Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial

Osamu Ishihara et al.

Summary: The individualized fixed-dose regimen of follitropin delta for ovarian stimulation in Japanese women is just as effective as conventional follitropin beta dosing in terms of number of oocytes retrieved, while significantly reducing the incidence of ovarian hyperstimulation syndrome (OHSS).

REPRODUCTIVE BIOMEDICINE ONLINE (2021)

Add to Collection

Review Endocrinology & Metabolism

Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017)

Human Fatemi et al.

Summary: Individualization of FSH starting dose is important during assisted reproductive technology treatment to avoid hyper- or hypo-ovarian response. This review found that in studies where dose adjustment was allowed and reported, the estimated incidence of r-hFSH dose adjustments during ovarian stimulation was up to 45%.

REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY (2021)

Add to Collection

Article Obstetrics & Gynecology

A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients

Jie Qiao et al.

Summary: Individualized stimulation with follitropin delta showed non-inferior ongoing pregnancy rate, higher live birth rate, and lower incidence of early OHSS compared to conventional follitropin alfa dosing in Asian population, demonstrating its potential to improve success rates with lower gonadotropin consumption.

HUMAN REPRODUCTION (2021)

Add to Collection

Article Genetics & Heredity

Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta

Jon Havelock et al.

Summary: The study compared the pregnancy and neonatal outcomes of fresh and frozen cycles using follitropin delta and follitropin alfa in assisted reproductive technology. The results showed similar overall take-home baby rates, ongoing implantation rates, and incidence of major congenital anomalies between the two treatment groups.

JOURNAL OF ASSISTED REPRODUCTION AND GENETICS (2021)

Add to Collection

Article Obstetrics & Gynecology

Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles

Manuel Fernandez-Sanchez et al.

REPRODUCTIVE BIOMEDICINE ONLINE (2019)

Add to Collection

Article Obstetrics & Gynecology

The number of oocytes retrieved during IVF: a balance between efficacy and safety

Asa Magnusson et al.

HUMAN REPRODUCTION (2018)

Add to Collection

Article Obstetrics & Gynecology

Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial

Anders Nyboe Andersen et al.

FERTILITY AND STERILITY (2017)

Add to Collection

Review Obstetrics & Gynecology

GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta- analysis accounting for patient type

C. B. Lambalk et al.

HUMAN REPRODUCTION UPDATE (2017)

Add to Collection

Article Obstetrics & Gynecology

Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles

M. Toftager et al.

HUMAN REPRODUCTION (2016)

Add to Collection

Article Obstetrics & Gynecology

Pregnancy and birth outcomes following fresh or vitrified embryo transfer according to blastocyst morphology and expansion stage, and culturing strategy for delayed development

B. Wirleitner et al.

HUMAN REPRODUCTION (2016)

Add to Collection

Review Medicine, General & Internal

Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

Hesham G. Al-Inany et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2016)

Add to Collection

Article Obstetrics & Gynecology

Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection

Joan-Carles Arce et al.

FERTILITY AND STERILITY (2014)

Add to Collection

Article Obstetrics & Gynecology

Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles

Ryan G. Steward et al.

FERTILITY AND STERILITY (2014)

Add to Collection

Review Medicine, General & Internal

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology

Mohamed A. F. M. Youssef et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)

Add to Collection

Review Endocrinology & Metabolism

Optimal usage of the GnRH antagonists: a review of the literature

Alan B. Copperman et al.

REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY (2013)

Add to Collection

Article Endocrinology & Metabolism

A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates

Jie Qiao et al.

GYNECOLOGICAL ENDOCRINOLOGY (2012)

Add to Collection

Article Obstetrics & Gynecology

The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting

et al.

HUMAN REPRODUCTION (2011)

Add to Collection

Article Obstetrics & Gynecology

Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes

K. P. Tremellen et al.

HUMAN REPRODUCTION (2010)

Add to Collection

Review Endocrinology & Metabolism

The science behind 25 years of ovarian stimulation for in vitro fertilization

NS Macklon et al.

ENDOCRINE REVIEWS (2006)

Add to Collection

Article Obstetrics & Gynecology

Increasing the gonadotrophin dose in the course of an in vitro fertilization cycle does not rectify an initial poor response

Y Khalaf et al.

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.